Myriad: Q1 Earnings Snapshot

May 5, 2022 GMT

SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Thursday reported a loss of $20.5 million in its first quarter.

The Salt Lake City-based company said it had a loss of 26 cents per share. Losses, adjusted for one-time gains and costs, were 3 cents per share.

The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 5 cents per share.

The molecular diagnostic company posted revenue of $164.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $158.6 million.

Myriad expects full-year results to range from a loss of 90 cents per share to earnings of 20 cents per share, with revenue in the range of $670 million to $700 million.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on MYGN at